Compare Prologis Inc (PLD) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prologis Inc vs Tempus AI — how do they compare? Prologis Inc trades at $136.97 (market cap $131.60B), while Tempus AI trades at $61.23 (market cap $11.67B). The key difference: Prologis Inc is far larger — about 11.3× Tempus AI's market cap, and Prologis Inc pays a 3.09% dividend while Tempus AI pays none. Which is the better fit depends on your goals.
| PLD | TEM | |
|---|---|---|
Market Cap | $131.60B | $11.67B |
Sector | Real Estate | Broad Market / Factor |
52-Week High | $149.96 | $103.25 |
52-Week Low | $110.98 | $41.55 |
Enterprise Value | $166.34B | $12.30B |
Dividend Yield | 3.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prologis (PLD) trades at $138.49, up 0.84% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.13 exceeding the $0.747 estimate. Revenue grew to $8.79 billion in 2025, though net income margin dipped to 37.86%. The stock faces headwinds from a high P/E of 30.84 and rising debt-to-asset ratio, now at 37.2% for 2025. Recent news highlights institutional buying interest amid market volatility.
The outlook for PLD is mixed, with analyst consensus bullish (59.52% buy ratings) and a $160.13 price target suggesting 15.6% upside. Key opportunities include sustained revenue growth and dividend stability, but risks involve elevated valuation, debt levels, and macroeconomic sensitivity. The stock's performance hinges on Q3 2026 earnings and the integration of the SEGRO acquisition.
Tempus AI (TEM) trades at $64.29, down 0.51% on the day, with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats despite negative profitability, with a P/S of 7.99 and P/B of 26.23. Recent catalysts include FDA clearance for an AI ECG product and a $9.5 million ARPA-H award for autonomous AI in cardiology (Business Wire, September 9, 2026).
Outlook remains positive given analyst consensus and growth in precision medicine, but risks include sustained losses, high valuation multiples, and cash burn. The consensus price target is $69.11, implying potential upside, though investors must weigh the company's unprofitability against its innovation pipeline and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
